OA11531A - Peptide compositions and formulations and use of same. - Google Patents
Peptide compositions and formulations and use of same. Download PDFInfo
- Publication number
- OA11531A OA11531A OA1200000249A OA1200000249A OA11531A OA 11531 A OA11531 A OA 11531A OA 1200000249 A OA1200000249 A OA 1200000249A OA 1200000249 A OA1200000249 A OA 1200000249A OA 11531 A OA11531 A OA 11531A
- Authority
- OA
- OAPI
- Prior art keywords
- glycine
- sequence
- valine
- alanine
- proline
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 139
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 238000009472 formulation Methods 0.000 title abstract description 9
- 102000016942 Elastin Human genes 0.000 claims abstract description 110
- 108010014258 Elastin Proteins 0.000 claims abstract description 110
- 229920002549 elastin Polymers 0.000 claims abstract description 110
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 37
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 37
- 239000002537 cosmetic Substances 0.000 claims abstract description 27
- 230000029087 digestion Effects 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
- 239000004471 Glycine Substances 0.000 claims description 226
- 238000000034 method Methods 0.000 claims description 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- 108090001109 Thermolysin Proteins 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 10
- FDJUEUDUCFJTBX-IYSQHNJGSA-N 2-aminoacetic acid (2S)-2-amino-3-methylbutanoic acid (2S,3S)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O.CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O FDJUEUDUCFJTBX-IYSQHNJGSA-N 0.000 claims description 8
- YBLDDXGNJXTBIA-YYCLPLPESA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid (2S)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CC1=CC=CC=C1 YBLDDXGNJXTBIA-YYCLPLPESA-N 0.000 claims description 8
- 239000004473 Threonine Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- NUDSUGKLNRMFQF-TVKLMDQASA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid (2S)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.NCC(O)=O.OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CC1=CC=CC=C1 NUDSUGKLNRMFQF-TVKLMDQASA-N 0.000 claims description 5
- BXFCLVNVRLYXEP-RSLHMRQOSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.NCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O BXFCLVNVRLYXEP-RSLHMRQOSA-N 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 206010029113 Neovascularisation Diseases 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000002528 coronary thrombosis Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- -1 aérosol Substances 0.000 claims 4
- ZVVYPSXJAHYKPU-FHNDMYTFSA-N 2-aminoacetic acid;(2s)-2-amino-3-methylbutanoic acid Chemical compound NCC(O)=O.NCC(O)=O.CC(C)[C@H](N)C(O)=O ZVVYPSXJAHYKPU-FHNDMYTFSA-N 0.000 claims 1
- YQWJKRXJKVPHPG-OMSMUOAWSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H](N)CC1=CC=CC=C1 YQWJKRXJKVPHPG-OMSMUOAWSA-N 0.000 claims 1
- PUGMFRRQDVPNSV-MSRFJDSMSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.OC(=O)[C@@H]1CCCN1.CC[C@H](C)[C@H](N)C(O)=O PUGMFRRQDVPNSV-MSRFJDSMSA-N 0.000 claims 1
- DDRAYWXTTWQAEA-HJXLNUONSA-N 2-aminoacetic acid;(2s,4r)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.O[C@H]1CN[C@H](C(O)=O)C1 DDRAYWXTTWQAEA-HJXLNUONSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 94
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 41
- 230000001225 therapeutic effect Effects 0.000 abstract description 18
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 238000007385 chemical modification Methods 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 88
- 210000003491 skin Anatomy 0.000 description 56
- 210000001519 tissue Anatomy 0.000 description 45
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 16
- 238000003776 cleavage reaction Methods 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000003041 ligament Anatomy 0.000 description 8
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 3
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 3
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 3
- YTPLVNUZZOBFFC-SCZZXKLOSA-N Val-Gly-Pro Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N1CCC[C@@H]1C(O)=O YTPLVNUZZOBFFC-SCZZXKLOSA-N 0.000 description 3
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108010029020 prolylglycine Proteins 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 210000000264 venule Anatomy 0.000 description 3
- PPINMSZPTPRQQB-NHCYSSNCSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PPINMSZPTPRQQB-NHCYSSNCSA-N 0.000 description 2
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091028026 C-DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NPLGQVKZFGJWAI-QWHCGFSZSA-N Phe-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O NPLGQVKZFGJWAI-QWHCGFSZSA-N 0.000 description 2
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 2
- JSOXWWFKRJKTMT-WOPDTQHZSA-N Val-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N JSOXWWFKRJKTMT-WOPDTQHZSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 101150089730 gly-10 gene Proteins 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 108010072644 valyl-alanyl-prolyl-glycine Proteins 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 1
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 1
- 241000193389 Bacillus thermoproteolyticus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- UCGDDTHMMVWVMV-FSPLSTOPSA-N Ile-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(O)=O UCGDDTHMMVWVMV-FSPLSTOPSA-N 0.000 description 1
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- KTNGVMMGIQWIDV-OSUNSFLBSA-N Ile-Pro-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O KTNGVMMGIQWIDV-OSUNSFLBSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- DPUYCSDGMSDKKV-MKBYFEBXSA-N N-Acetyl-L-leucyl-L-isoleucylglycyl-L-valyl-N-methyl-L-prolinamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC DPUYCSDGMSDKKV-MKBYFEBXSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- DPUOLKQSMYLRDR-UBHSHLNASA-N Phe-Arg-Ala Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 DPUOLKQSMYLRDR-UBHSHLNASA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 1
- PMKQKNBISAOSRI-XHSDSOJGSA-N Val-Tyr-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N PMKQKNBISAOSRI-XHSDSOJGSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- LBZXELUWKIEZEQ-MYINAIGISA-N [[(2r,3s,5s)-5-bromo-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@]1(Br)N1C(=O)NC(=O)C=C1 LBZXELUWKIEZEQ-MYINAIGISA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108010043293 glycyl-prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010069589 glycyl-valyl-glycyl-valyl-proline Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000006498 vasomotor response Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Birds (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/039,308 US6069129A (en) | 1998-03-13 | 1998-03-13 | Elastin derived composition and method of using same |
PCT/US1999/005496 WO1999045941A1 (en) | 1998-03-13 | 1999-03-12 | Peptide compositions and formulations and use of same |
Publications (1)
Publication Number | Publication Date |
---|---|
OA11531A true OA11531A (en) | 2004-05-06 |
Family
ID=21904781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200000249A OA11531A (en) | 1998-03-13 | 1999-03-12 | Peptide compositions and formulations and use of same. |
Country Status (19)
Country | Link |
---|---|
US (2) | US6069129A (de) |
EP (1) | EP1064010B1 (de) |
JP (1) | JP2002506041A (de) |
KR (1) | KR100612535B1 (de) |
CN (1) | CN100364606C (de) |
AP (1) | AP2000001905A0 (de) |
AT (1) | ATE386536T1 (de) |
AU (1) | AU765379B2 (de) |
BR (1) | BR9908749A (de) |
CA (1) | CA2322839A1 (de) |
DE (1) | DE69938174T2 (de) |
EA (1) | EA003857B1 (de) |
HK (1) | HK1036225A1 (de) |
ID (1) | ID28270A (de) |
IL (2) | IL138453A0 (de) |
NO (1) | NO325371B1 (de) |
NZ (1) | NZ506898A (de) |
OA (1) | OA11531A (de) |
WO (1) | WO1999045941A1 (de) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962904B1 (en) * | 1998-03-13 | 2005-11-08 | Connective Tissue Imagineering | Elastin peptide analogs and uses thereof |
US6809075B1 (en) * | 2000-05-30 | 2004-10-26 | Connective Tissue Imagineering Llc | Elastin peptide analogs and uses of same incombination with skin enhancing agents |
US6777389B1 (en) * | 1998-11-19 | 2004-08-17 | Connective Tissue Imagineering Llc | Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides |
US6903244B1 (en) | 1999-02-26 | 2005-06-07 | University Of Utah Research Foundation | Mice which are +/− or −/− for the elastin gene as models for vascular disease |
EP1300418A1 (de) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Genregulation durch Oligopeptide |
US6794362B1 (en) * | 2000-05-30 | 2004-09-21 | Connective Tissue Imagineering Llc | Asparagine containing elastin peptide analogs |
AU2001275018B2 (en) * | 2000-05-30 | 2008-04-03 | Connective Tissue Imagineering Llc | Composition and method for enhancing elasticity of tissue |
SG98420A1 (en) * | 2000-07-13 | 2003-09-19 | Purzer Pharmaceutical Co Ltd | Method for transferring one or more active ingredients between different phase carriers |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
US20030198631A1 (en) * | 2002-04-18 | 2003-10-23 | Healthpoint, Ltd. | Thermolysin enzymatic wound debrider |
WO2004073616A2 (en) * | 2003-02-14 | 2004-09-02 | Human Matrix Sciences Llc | Elastin digest compositions and methods utilizing same |
FR2854897B1 (fr) * | 2003-05-12 | 2007-05-04 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane. |
US6927206B2 (en) * | 2003-06-06 | 2005-08-09 | Procyte Corporation | Compositions and methods for treatment of rosacea |
GB0313644D0 (en) * | 2003-06-12 | 2003-07-16 | Univ Bristol | Inhibition of infection |
US20050063932A1 (en) * | 2003-08-14 | 2005-03-24 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
US20060198800A1 (en) * | 2003-08-14 | 2006-09-07 | Natalie Dilallo | Skin care compositions including hexapeptide complexes and methods of their manufacture |
US7803522B2 (en) * | 2004-02-13 | 2010-09-28 | Human Matrix Sciences, Llc | Elastin producing fibroblast formulations and methods of using the same |
CA2562871C (en) | 2004-02-20 | 2014-06-10 | Human Matrix Sciences, Llc | Iron based compounds for elastogenesis and connective tissue treatment |
US7392611B2 (en) * | 2004-12-22 | 2008-07-01 | Smith & Wesson Corp. | Apparatus and method for firearm takedown |
US8114829B2 (en) * | 2005-02-22 | 2012-02-14 | Human Matrix Sciences, Llc | Elastin protective polyphenolics and methods of using the same |
US8642578B2 (en) | 2005-03-29 | 2014-02-04 | Human Matrix Sciences, Llc | Elastin protective polyphenolics and methods of using the same |
CA2608747C (en) | 2005-05-17 | 2013-01-22 | Human Matrix Sciences, Llc | Elastin producing fibroblast formulations and methods of using the same |
JP2007045722A (ja) * | 2005-08-08 | 2007-02-22 | Kyushu Institute Of Technology | 水溶性エラスチンとそれを含む食品及び医薬 |
CA2652388A1 (en) | 2006-05-15 | 2007-11-22 | Valio Ltd | New use of therapeutically useful peptides |
US8778376B2 (en) | 2006-06-09 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating |
JP5276813B2 (ja) * | 2006-08-25 | 2013-08-28 | 日本ハム株式会社 | エラスチン分解ペプチド並びにエラスチン及びその酵素分解ペプチドの製造方法 |
US8828354B2 (en) | 2008-03-27 | 2014-09-09 | Warsaw Orthopedic, Inc. | Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
US20090264478A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Sulfasalazine formulations in a biodegradable polymer carrier |
US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US8956641B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US9125917B2 (en) * | 2008-04-18 | 2015-09-08 | Warsaw Orthopedic, Inc. | Fluocinolone formulations in a biodegradable polymer carrier |
US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
US20090263451A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain |
US9289409B2 (en) * | 2008-04-18 | 2016-03-22 | Warsaw Orthopedic, Inc. | Sulindac formulations in a biodegradable material |
US9132119B2 (en) | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US9132085B2 (en) * | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US8956636B2 (en) | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprosing ketorolac |
US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US20100015049A1 (en) * | 2008-07-16 | 2010-01-21 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
US9492375B2 (en) * | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
JP2010155820A (ja) * | 2008-10-10 | 2010-07-15 | Hayashikane Sangyo Kk | 皮膚改善剤、血管改善剤、並びにこれらを含む医薬組成物、食品、飼料及び化粧品 |
US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
US9161903B2 (en) | 2008-10-31 | 2015-10-20 | Warsaw Orthopedic, Inc. | Flowable composition that hardens on delivery to a target tissue site beneath the skin |
US8980317B2 (en) | 2008-12-23 | 2015-03-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating infections comprising a local anesthetic |
US20100226959A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Matrix that prolongs growth factor release |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
US8617583B2 (en) | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
US8653029B2 (en) | 2009-07-30 | 2014-02-18 | Warsaw Orthopedic, Inc. | Flowable paste and putty bone void filler |
US8231891B2 (en) | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
US20110097380A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Clonidine formulations having antimicrobial properties |
US9504698B2 (en) * | 2009-10-29 | 2016-11-29 | Warsaw Orthopedic, Inc. | Flowable composition that sets to a substantially non-flowable state |
US8597192B2 (en) | 2009-10-30 | 2013-12-03 | Warsaw Orthopedic, Inc. | Ultrasonic devices and methods to diagnose pain generators |
US8475824B2 (en) * | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
US8758791B2 (en) * | 2010-01-26 | 2014-06-24 | Warsaw Orthopedic, Inc. | Highly compression resistant matrix with porous skeleton |
US9125902B2 (en) * | 2010-01-28 | 2015-09-08 | Warsaw Orthopedic, Inc. | Methods for treating an intervertebral disc using local analgesics |
US9050274B2 (en) * | 2010-01-28 | 2015-06-09 | Warsaw Orthopedic, Inc. | Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents |
US9486500B2 (en) | 2010-01-28 | 2016-11-08 | Warsaw Orthopedic, Inc. | Osteoimplant and methods for making |
US8246571B2 (en) | 2010-08-24 | 2012-08-21 | Warsaw Orthopedic, Inc. | Drug storage and delivery device having a retaining member |
JP6083085B2 (ja) * | 2010-09-08 | 2017-02-22 | 国立大学法人九州工業大学 | アンジオテンシン変換酵素阻害剤およびその用途 |
US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
US8740982B2 (en) | 2010-10-26 | 2014-06-03 | Kyphon Sarl | Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis |
US9414930B2 (en) | 2010-10-26 | 2016-08-16 | Kyphon SÀRL | Activatable devices containing a chemonucleolysis agent |
US9301946B2 (en) | 2010-12-03 | 2016-04-05 | Warsaw Orthopedic, Inc. | Clonidine and GABA compounds in a biodegradable polymer carrier |
WO2012075447A2 (en) | 2010-12-03 | 2012-06-07 | Warsaw Orthopedic, Inc. | Compositions and methods for delivering clonidine and bupivacaine to a target tissue site |
US9060978B2 (en) | 2011-01-24 | 2015-06-23 | Warsaw Orthopedic, Inc. | Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist |
US9717779B2 (en) | 2011-01-31 | 2017-08-01 | Warsaw Orthopedic, Inc. | Implantable matrix having optimum ligand concentrations |
CN103458911B (zh) * | 2011-02-11 | 2016-02-24 | 密歇根大学董事会 | 肽组合物和用于治疗患者的方法 |
US9592243B2 (en) | 2011-04-25 | 2017-03-14 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an anabolic agent for treatment of an injury |
US9511077B2 (en) | 2011-04-25 | 2016-12-06 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an anabolic agent for wound healing |
US9132194B2 (en) | 2011-07-12 | 2015-09-15 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an adhesive sheet containing a drug depot |
US9205241B2 (en) | 2011-07-12 | 2015-12-08 | Warsaw Orthopedic, Inc. | Medical devices and methods comprising an adhesive material |
US9511018B2 (en) | 2012-04-05 | 2016-12-06 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable matrix |
US8735504B2 (en) | 2012-05-02 | 2014-05-27 | Warsaw Orthopedic, Inc. | Methods for preparing polymers having low residual monomer content |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
KR101706296B1 (ko) | 2015-12-21 | 2017-02-13 | 주식회사 브레인온 | 기억력, 학습력, 인지력 향상용 조성물 |
RU2694064C1 (ru) | 2015-12-21 | 2019-07-09 | Браинон Инк. | Композиция для улучшения памяти, способности к обучению и когнитивных способностей |
US10549081B2 (en) | 2016-06-23 | 2020-02-04 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
KR102504364B1 (ko) * | 2016-10-04 | 2023-02-28 | 주식회사 엘지생활건강 | 류신 유도체, 이를 포함하는 조성물 및 이의 용도 |
CN115919994A (zh) * | 2016-10-04 | 2023-04-07 | 株式会社Lg生活健康 | 亮氨酸衍生物、包含其的组合物及其用途 |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
KR102007079B1 (ko) * | 2017-03-24 | 2019-10-02 | (주)셀아이콘랩 | 펩타이드를 활용한 피부의 노화 억제용 조성물 및 세포노화 억제와 주름개선을 위한 화장품 조성물 |
GB201711360D0 (en) | 2017-07-14 | 2017-08-30 | Raft Entpr Ltd | Tissue scaffold |
JP2019112401A (ja) * | 2017-12-22 | 2019-07-11 | 株式会社バイタルリソース応用研究所 | アンジオテンシン変換酵素阻害化合物 |
CN108261539A (zh) * | 2018-02-27 | 2018-07-10 | 南京圣诺生物科技实业有限公司 | 一种用于抗血栓的组合物、其制备方法及用途 |
CN108588155A (zh) * | 2018-04-18 | 2018-09-28 | 珀莱雅化妆品股份有限公司 | 一种酶解猪动脉血管制备弹力蛋白肽的方法 |
US20230234986A1 (en) * | 2020-05-22 | 2023-07-27 | Sunshine Biopharma Inc. | Inhibitors of coronavirus protease |
FR3116273B1 (fr) * | 2020-11-17 | 2023-10-27 | Sederma Sa | Tétrapeptides, compositions les comprenant et leur utilisation cosmétique |
KR20230047692A (ko) * | 2021-10-01 | 2023-04-10 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
KR102484277B1 (ko) * | 2021-11-22 | 2023-01-04 | 대한켐텍 주식회사 | 피부 미용 개선용 원료 조성물의 제조방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7713618A (nl) * | 1976-12-11 | 1978-06-13 | Bayer Ag | Werkwijze voor de bereiding van een cosmetisch preparaat. |
DE2705670C3 (de) * | 1977-02-11 | 1983-11-17 | Fa. Carl Freudenberg, 6940 Weinheim | Verfahren zur Herstellung von wasserlöslichen Elastin-Hydrolysaten |
US4591501A (en) * | 1981-04-13 | 1986-05-27 | Seton Company | Cosmetic and pharmaceutical sheet material containing polypeptides |
US4474763A (en) * | 1982-07-07 | 1984-10-02 | Lubowe Irwin I | Skin preparation |
US4659740A (en) * | 1985-02-14 | 1987-04-21 | Polydex Pharmaceuticals Ltd. | Cosmetic preparations comprising novel elastin derivatives |
US5223420A (en) * | 1985-03-01 | 1993-06-29 | Institut National De La Sante Et De La Recherche Medicale | Elastin-based product, a procedure for its preparation and its biological applications; in particular as biomaterials and artificial supports |
US5017691A (en) * | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
JP2549118B2 (ja) * | 1987-05-30 | 1996-10-30 | 三省製薬株式会社 | 乳化組成物 |
US5079003A (en) * | 1990-03-14 | 1992-01-07 | Adelia Scaffidi | Skin lotions and creams |
US5523291A (en) * | 1993-09-07 | 1996-06-04 | Datascope Investment Corp. | Injectable compositions for soft tissue augmentation |
FR2721031B1 (fr) * | 1994-06-09 | 1996-07-26 | Centre Nat Rech Scient | Fragment peptidique spécifique du virus de l'immunodéficience féline (VIF) et son utilisation comme réactif de diagnostic. |
JP2863898B2 (ja) * | 1995-02-21 | 1999-03-03 | 末綱 陽子 | 新規なペプチドおよび免疫賦活剤 |
US5945409A (en) * | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
JP2012225594A (ja) * | 2011-04-21 | 2012-11-15 | Panasonic Corp | 製氷装置 |
-
1998
- 1998-03-13 US US09/039,308 patent/US6069129A/en not_active Expired - Fee Related
-
1999
- 1999-03-12 AP APAP/P/2000/001905A patent/AP2000001905A0/en unknown
- 1999-03-12 AU AU30854/99A patent/AU765379B2/en not_active Ceased
- 1999-03-12 WO PCT/US1999/005496 patent/WO1999045941A1/en active IP Right Grant
- 1999-03-12 ID IDW20002053A patent/ID28270A/id unknown
- 1999-03-12 CN CNB998059390A patent/CN100364606C/zh not_active Expired - Fee Related
- 1999-03-12 EP EP99912486A patent/EP1064010B1/de not_active Expired - Lifetime
- 1999-03-12 KR KR1020007010112A patent/KR100612535B1/ko not_active IP Right Cessation
- 1999-03-12 CA CA002322839A patent/CA2322839A1/en not_active Abandoned
- 1999-03-12 OA OA1200000249A patent/OA11531A/en unknown
- 1999-03-12 DE DE69938174T patent/DE69938174T2/de not_active Expired - Fee Related
- 1999-03-12 JP JP2000535355A patent/JP2002506041A/ja active Pending
- 1999-03-12 NZ NZ506898A patent/NZ506898A/en unknown
- 1999-03-12 BR BR9908749-9A patent/BR9908749A/pt not_active Application Discontinuation
- 1999-03-12 EA EA200000933A patent/EA003857B1/ru unknown
- 1999-03-12 IL IL13845399A patent/IL138453A0/xx active IP Right Revival
- 1999-03-12 AT AT99912486T patent/ATE386536T1/de not_active IP Right Cessation
-
2000
- 2000-05-30 US US09/584,001 patent/US6506731B1/en not_active Expired - Fee Related
- 2000-09-12 NO NO20004540A patent/NO325371B1/no not_active IP Right Cessation
- 2000-09-13 IL IL138453A patent/IL138453A/en not_active IP Right Cessation
-
2001
- 2001-10-11 HK HK01107123A patent/HK1036225A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO325371B1 (no) | 2008-04-14 |
BR9908749A (pt) | 2001-10-09 |
HK1036225A1 (en) | 2001-12-28 |
CN100364606C (zh) | 2008-01-30 |
NO20004540L (no) | 2000-11-09 |
DE69938174T2 (de) | 2009-01-08 |
AP2000001905A0 (en) | 2000-09-30 |
NO20004540D0 (no) | 2000-09-12 |
US6506731B1 (en) | 2003-01-14 |
CA2322839A1 (en) | 1999-09-16 |
EP1064010B1 (de) | 2008-02-20 |
DE69938174D1 (de) | 2008-04-03 |
ATE386536T1 (de) | 2008-03-15 |
AU765379B2 (en) | 2003-09-18 |
IL138453A (en) | 2007-07-24 |
CN1300220A (zh) | 2001-06-20 |
EA200000933A1 (ru) | 2001-04-23 |
IL138453A0 (en) | 2001-10-31 |
AU3085499A (en) | 1999-09-27 |
EP1064010A1 (de) | 2001-01-03 |
EP1064010A4 (de) | 2004-10-06 |
US6069129A (en) | 2000-05-30 |
ID28270A (id) | 2001-05-10 |
NZ506898A (en) | 2003-05-30 |
WO1999045941A1 (en) | 1999-09-16 |
EA003857B1 (ru) | 2003-10-30 |
JP2002506041A (ja) | 2002-02-26 |
KR100612535B1 (ko) | 2006-08-11 |
KR20010041827A (ko) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU765379B2 (en) | Peptide compositions and formulations and use of same | |
US9458197B2 (en) | Elastin digest compositions and methods utilizing same | |
EP2402369B1 (de) | Peptidfragmente zur Induzierung der Synthese extrazellulärer Matrixproteine | |
US6794362B1 (en) | Asparagine containing elastin peptide analogs | |
US6777389B1 (en) | Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides | |
US7666842B2 (en) | Elastin peptide analogs and uses thereof | |
EP1054677B1 (de) | Kosmetische oder dermatologische verwendung von 7-hydroxylierten steroiden aleine oder zusammen mit von elastin abgeleiteten peptiden | |
NZ524930A (en) | Elastin peptide compositions and formulations and use of same | |
AU2007201615A1 (en) | Peptide compositions and formulations and use of same | |
AU2003270980A1 (en) | Peptide Compositions and Formulations and Use of Same | |
US6809075B1 (en) | Elastin peptide analogs and uses of same incombination with skin enhancing agents | |
CN114432176A (zh) | 一种靶向肽修饰的美容肽组合物 | |
MXPA00008979A (en) | Peptide compositions and formulations and use of same | |
US8778891B2 (en) | Dermatopontin-activating peptides and cosmetic compositions including same | |
KR20180047207A (ko) | 항노화 펩타이드와 베타글루칸을 함유하는 피부 재생 및 보습 화장료 조성물 | |
AU2012216555B2 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
MXPA00007044A (en) | Cosmetic or dermatological use of 7-hydroxylated steroids alone and/or in combination with elastin derived peptides | |
JP2005531539A (ja) | ペプチド組成物 |